By otakuyassine3@gmail.com 
Novartis AG (NYSE:NVS – Free Report) – Investment analysts at Zacks Research upped their FY2024 EPS estimates for Novartis in a note issued to investors on Thursday, December 12th. Zacks Research analyst E. Bagri now expects that the company will earn $7.60 per share for the year, up from their prior forecast of $7.59. The consensus estimate for Novartis’ current full-year earnings is $7.65 per share. Zacks Research also issued estimates for Novartis’ Q1 2025 earnings at $1.96 EPS, Q2 2025 earnings at $2.10 EPS and Q1 2026 earnings at $2.09 EPS.
Novartis (NYSE:NVS – Get Free Report) last issued its quarterly earnings data on Tuesday, October 29th. The company reported $2.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.94 by $0.12. The firm had revenue of $12.82 billion during the quarter, compared to the consensus estimate of $12.62 billion. Novartis had a return on equity of 34.80% and a net margin of 35.96%. During the same period last year, the company earned $1.74 EPS.
Several other equities research analysts have also commented on the stock. BMO Capital Markets lifted their price target on shares of Novartis from $118.00 to $120.00 and gave the stock a “market perform” rating in a research note on Wednesday, October 30th. HSBC lowered shares of Novartis from a “hold” rating to a “reduce” rating in a research note on Wednesday, December 4th. Erste Group Bank reiterated a “hold” rating on shares of Novartis in a research note on Tuesday, November 19th. Jefferies Financial Group cut shares of Novartis from a “buy” rating to a “hold” rating in a research note on Tuesday, September 3rd. Finally, Bank of America lowered shares of Novartis from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $135.00 to $130.00 in a research note on Wednesday, September 11th. Two research analysts have rated the stock with a sell rating and seven have given a hold rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $121.50.
Get Our Latest Analysis on Novartis
Novartis Stock Performance
Shares of Novartis stock opened at $99.10 on Monday. Novartis has a one year low of $92.35 and a one year high of $120.92. The business has a 50-day simple moving average of $107.33 and a 200-day simple moving average of $110.23. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.90 and a current ratio of 1.11. The company has a market cap of $202.56 billion, a PE ratio of 11.51, a P/E/G ratio of 1.49 and a beta of 0.56.
Institutional Investors Weigh In On Novartis
A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Raymond James & Associates lifted its holdings in Novartis by 1.3% during the second quarter. Raymond James & Associates now owns 536,607 shares of the company’s stock worth $57,127,000 after acquiring an additional 6,767 shares during the period. MONECO Advisors LLC purchased a new stake in Novartis during the second quarter worth about $217,000. Nisa Investment Advisors LLC increased its holdings in Novartis by 2,272.7% during the second quarter. Nisa Investment Advisors LLC now owns 522 shares of the company’s stock worth $56,000 after buying an additional 500 shares during the last quarter. Raymond James Financial Services Advisors Inc. boosted its stake in Novartis by 4.9% in the second quarter. Raymond James Financial Services Advisors Inc. now owns 354,449 shares of the company’s stock valued at $37,735,000 after acquiring an additional 16,492 shares during the last quarter. Finally, First Horizon Advisors Inc. grew its position in shares of Novartis by 21.0% during the 2nd quarter. First Horizon Advisors Inc. now owns 14,066 shares of the company’s stock valued at $1,497,000 after acquiring an additional 2,439 shares during the period. 13.12% of the stock is owned by hedge funds and other institutional investors.
About Novartis
Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.
Featured Articles
Receive News & Ratings for Novartis Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Novartis and related companies with MarketBeat.com’s FREE daily email newsletter.